10-Q: Nutra Pharma Q2 Loss Widens Amid Debt & Legal Woes

Nutra Pharma Corp. reported a significant net loss for Q2 2023, driven by derivative fair value changes and ongoing liquidity concerns, despite increased product sales.

Summary

• Net loss for the six months ended June 30, 2023, was $871,806, a substantial decrease from a net income of $4,367,662 in the prior-year period.
• Total net sales increased by 184.1% to $319,911 for the six months ended June 30, 2023, compared to $112,576 in the same period of 2022.
• Gross profit surged by 402.3% to $187,734, with gross profit margin improving to 58.68% from 33.2% year-over-year.
• The company faces substantial doubt about its ability to continue as a going concern, with an accumulated deficit of $74,423,924, a working capital deficit of $13,276,462, and a stockholders deficit of $13,249,258 as of June 30, 2023.
• Disclosure controls and procedures were deemed ineffective due to material weaknesses in internal control over financial reporting.
• A final judgment in the SEC lawsuit issued in July 2024 ordered the company to pay $520,940 in disgorgement, $59,295 in prejudgment interest, and a $100,000 civil penalty.
• A settlement was reached in the CSA 8411, LLC lawsuit on May 19, 2025, for $125,000, resolving a $178,526 obligation and expected to result in a $53,526 gain on settlement upon full payment.

Sentiment

Score: 2

Explanation: The company faces severe liquidity issues, substantial accumulated deficits, and ongoing legal and operational challenges. While sales increased and gross margin improved, the significant net loss, ineffective controls, and reliance on high-cost debt financing paint a very negative financial picture with substantial doubt about its going concern ability.

Positives

• Net sales to unrelated customers increased by 153.42% to $106,920 for the six months ended June 30, 2023.
• Net sales to a related party increased by 202.6% to $212,991 for the six months ended June 30, 2023, reflecting stronger demand for existing products.
• Gross profit margin significantly improved to 58.68% for the six months ended June 30, 2023, from 33.2% in the prior year, primarily due to lower manufacturing costs.
• Loss from operations decreased to $580,990 for the six months ended June 30, 2023, from $649,510 in the prior year.
• Interest expense decreased by 40.71% to $233,075 for the six months ended June 30, 2023.
• A settlement agreement in the CSA 8411, LLC lawsuit on May 19, 2025, resolved a $178,526 obligation for $125,000, expected to result in a $53,526 gain on settlement.

Negatives

• Reported a net loss of $871,806 for the six months ended June 30, 2023, a significant decline from a net income of $4,367,662 in the same period of 2022.
• Accumulated deficit reached $74,423,924 as of June 30, 2023.
• Working capital deficit was $13,276,462 and stockholders deficit was $13,249,258 as of June 30, 2023.
• The company has a significant amount of indebtedness in default.
• Bad debt expense from related parties increased to $105,465 for the six months ended June 30, 2023, from $21,799 in the prior year.
• A negative swing of $5,640,030 in the change in fair value of convertible notes and derivatives, from a gain of $5,549,845 in 2022 to a loss of $90,185 in 2023.
• The company has no cash or cash equivalents as of June 30, 2023 and December 31, 2022.
• Disclosure controls and procedures were not effective due to material weaknesses in internal control over financial reporting.
• A final judgment in the SEC lawsuit ordered the company to pay $520,940 in disgorgement, $59,295 in prejudgment interest, and a $100,000 civil penalty.
• The company's common stock is on the OTC Market Groups Expert Market, limiting its ability to raise capital.

Risks

• Substantial doubt about the ability to continue as a going concern due to recurring losses, significant deficits, and insufficient cash.
• Reliance on debt and equity funding, which has historically been insufficient to execute the business plan.
• Inability to secure additional financing on acceptable terms or at all, which could prevent implementation of expansion plans and repayment of obligations.
• Exposure to risks associated with developing and commercializing products from research and development activities.
• Intense competition in the biotechnology area could negatively impact operations and market position.
• Potential adverse effects from failure to successfully execute planned partnering and out-licensing of products or technologies.
• Biotechnology industry litigation is substantial and may lead to increased costs and unpredictable outcomes.
• Failure to comply with extensive legal/regulatory requirements in the healthcare industry could result in increased costs, penalties, and business losses.
• The common stock being on the OTC Market Groups Expert Market limits the ability to raise capital.
• Significant amount of indebtedness is in default.
• Material weaknesses in internal control over financial reporting indicate a risk of misstatements in financial reporting.

Future Outlook

The company plans to re-engage in the regulatory approval process for Nyloxin in Canada in 2026, pending adequate funding. It also aims to complete human clinical studies comparing Nyloxin Extra Strength to prescription pain relievers, but no timeline is available until adequate financing is secured. For its drug pipeline, the goal is to initiate Phase I/II trials for RPI78M in pediatric Multiple Sclerosis in 2026. The company estimates needing approximately $600,000 to fund existing operations over the next twelve months.

Management Comments

• Our business during the six months ended June 30, 2023 has focused upon marketing our homeopathic drugs for the treatment of pain.
• Our goal is that with Nyloxin, we can greatly reduce the instances of opiate abuse and overuse of NSAIDS in high risk groups like the US military.
• We have continued to work with our consultants to understand why our products were improperly removed the Federal Supply Schedule and when we may be able to get re-listed.
• Due to lack of funding and then the subsequent COVID crisis, we have waited to complete the approval process to begin distributing Nyloxin [in Canada] and expect to re-engage in the process in 2026.
• We cannot provide any timeline for these studies [human clinical studies for Nyloxin Extra Strength] until adequate financing is available.
• To date, our marketing efforts have been limited due to lack of funding. As sales increase, we plan to begin marketing more aggressively.
• Our goal is to initiate these trials [Phase I/II for RPI78M] in 2026.
• As of the date of the filing of this report, we do not believe that our source of cash is adequate for the next 12 months of operation and there is substantial doubt about our ability to continue as a going concern.

Industry Context

Nutra Pharma operates in the biotechnology and over-the-counter (OTC) pain relief markets. Its focus on non-opioid, non-NSAID pain relievers like Nyloxin aligns with growing public health concerns regarding opioid addiction and NSAID side effects. The company's drug discovery efforts for HIV and MS, particularly RPI78M's Orphan Status for pediatric MS, position it in specialized, high-need therapeutic areas within the biotech industry, which typically involve lengthy and capital-intensive development cycles. However, the company's limited funding and OTC Expert Market listing hinder its ability to compete effectively with larger pharmaceutical and biotech firms.

Comparison to Industry Standards

• The company's recurring significant losses and substantial accumulated deficit are well below industry standards for a healthy, growing biotechnology or pharmaceutical company.
• Operating with zero cash and a significant working capital deficit is a critical red flag, indicating severe liquidity issues compared to industry peers who typically maintain robust cash reserves for R&D and operations.
• The reliance on convertible notes with high discounts and variable conversion terms, often in default, suggests a distressed financing environment, unlike established biotech firms that access more favorable capital markets.
• The ineffectiveness of disclosure controls and procedures is a serious corporate governance concern, falling short of the transparency and internal control standards expected in publicly traded companies, especially compared to well-governed industry leaders.
• While RPI78M's Orphan Status for pediatric MS is a positive development, the inability to provide a timeline for Phase I/II trials due to lack of funding contrasts sharply with well-funded biotech companies that progress through clinical stages more predictably.
• The company's common stock being on the OTC Market Groups Expert Market indicates a lack of market access and investor confidence compared to companies listed on major exchanges like NASDAQ or NYSE.

Management Changes

Corporate Governance

Legal Proceedings

• CSA 8411, LLC v. Nutra Pharma Corp. (Case No. CACE 18-023150): Lawsuit filed October 12, 2018, to recover $100,000 allegedly owed under an amended promissory note. Settled on May 19, 2025, for $125,000, resolving a total liability of $178,526 (principal $91,156, accrued interest $87,370). Settlement terms include an initial payment of $35,000 and nine monthly payments of $10,000. Default on payments could lead to a $400,000 consent judgment.
• Securities and Exchange Commission v. Nutra Pharma Corporation, Erik Deitsch, and Sean Peter McManus (Case No. 2:18-cv-05459): Lawsuit filed September 28, 2018, alleging fraud and violations of anti-fraud and other securities laws, including unregistered private placements, false press releases, false statements in a Form 10-Q, and failure to disclose stock issuances. A final judgment was issued in July 2024, ordering the company to pay $520,940 in disgorgement, $59,295 in prejudgment interest, and a $100,000 civil penalty. Total accrued legal settlement amount of $680,235 as of June 30, 2023.

Related Party Transactions

• The company acts as a product formulator and contract manufacturer for Avini Health, a company owned and controlled by the company's former CEO, Rik Deitsch.
• The company sublets a portion of its space to Avini Health for a monthly rent of $5,000, with the first three months rent-free, commencing May 2022.
• A loan of $200,000 from a director (personally guaranteed by Mr. Deitsch) is in default regarding interest payments, with $158,963 in accrued interest owed as of June 30, 2023.
• A net balance of $466,568 is due to Rik Deitsch (former CEO) and his controlled companies as of June 30, 2023, unsecured and accruing interest at 4%.
• Accrued payroll due to officers totaled $1,293,693 as of June 30, 2023.
• Deferred revenue from a related party amounted to $312,173 as of June 30, 2023.
• Bad debt expense from receivables from companies controlled by the former CEO was $105,465 for the six months ended June 30, 2023.
• These transactions were not conducted on an arms-length basis and may differ from terms negotiated with unrelated third parties.

Stakeholder Impact

• Shareholders: Significant dilution risk from potential future equity raises and conversions of numerous convertible notes. The substantial accumulated deficit and going concern doubt pose a high risk to investment value. The common stock being on the OTC Expert Market limits trading and liquidity.
• Creditors: Many debts are in default, indicating high credit risk. Settlements of legal proceedings and debt obligations will consume resources.
• Employees/Officers: Accrued payroll due to officers of $1,293,693 suggests delayed compensation, potentially impacting morale and retention.
• Customers: Continued product sales growth is positive, but the company's financial instability could pose risks to product availability or future innovation.
• Regulatory Authorities: The SEC lawsuit and findings of ineffective disclosure controls highlight regulatory non-compliance issues.

Next Steps

• Secure additional financing to fund operations and execute the operating plan.
• Increase ownership equity and attain profitable operations.
• Re-engage in the regulatory approval process for Nyloxin in Canada in 2026.
• Complete human clinical studies for Nyloxin Extra Strength, pending adequate financing.
• Initiate Phase I/II trials for RPI78M in pediatric Multiple Sclerosis in 2026.
• Market products more aggressively as sales increase.
• Address material weaknesses in internal control over financial reporting.
• Make payments for the SEC lawsuit judgment ($520,940 disgorgement, $59,295 prejudgment interest, $100,000 civil penalty).
• Make payments for the CSA 8411, LLC settlement ($35,000 initial, then nine monthly payments of $10,000).
• Continue negotiations for settlement of various defaulted promissory and convertible notes.

Key Dates

Recommendation

The company faces severe financial distress, evidenced by a substantial net loss, accumulated deficit exceeding $74 million, zero cash, and significant working capital and stockholders deficits. The 'going concern' warning is explicit, and the company's reliance on high-cost, often defaulted, convertible debt for funding is unsustainable. Furthermore, the ineffectiveness of disclosure controls and the substantial penalties from the SEC lawsuit indicate severe governance and compliance issues. While sales growth and gross margin improvement are noted, they are insufficient to offset the overwhelming financial and operational challenges. The stock's listing on the OTC Expert Market further limits liquidity and investor interest. Given these critical issues, the risk of further value erosion or even bankruptcy is extremely high.

Keywords

Nutra Pharma, ReceptoPharm, Biotechnology, Pain Relievers, OTC Drugs, Nyloxin, Pet Pain-Away, Equine Pain-Away, Luxury Feet, Drug Discovery, HIV Treatment, Multiple Sclerosis Treatment, RPI78M, RPIMN, SEC Filing, 10-Q, Financial Reporting, Going Concern, Convertible Debt, Litigation, Pharmaceuticals, Orphan Drug Status